Evidence map›Paper›PMID 34324607›Full record

ReviewPLoS pathogens2021

Azole-resistant Aspergillus fumigatus in the environment: Identifying key reservoirs and hotspots of antifungal resistance.

Caroline Burks, Alexandria Darby, Luisa Gómez Londoño, Michelle Momany, Marin T Brewer

Open access · goldAbstract readReview
In one paragraph

Review in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 140 citations in OpenAlex.

  1. Article
  2. Ten-Year Voriconazole Susceptibility Trends Among 1482 ClinicalJournal of fungi (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Thermal adaptation crosstalk with azole response through lncRNA inbioRxiv : the preprint server for biology · 2026
    Article
  10. Directed evolution of the pathogenic moldAntimicrobial agents and chemotherapy · 2026
    Article
  11. Azole Resistance inOpen forum infectious diseases · 2026
    Article
  12. Global epidemiology of azole resistance inJAC-antimicrobial resistance · 2026
    Review
  13. A One Health Perspective onJournal of fungi (Basel, Switzerland) · 2026
    Article
  14. Review
  15. Review
  16. Understanding multi-azole resistance inFrontiers in fungal biology · 2026
    Article
  17. Review
  18. Article
  19. Review
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Caroline BurksPlant Pathology Department and Fungal Biology Group, University of Georgia, Athens, Georgia, United States of America.ORCID 0000-0002-9751-2904
Alexandria DarbyPlant Pathology Department and Fungal Biology Group, University of Georgia, Athens, Georgia, United States of America.ORCID 0000-0001-9083-8197
Luisa Gómez LondoñoPlant Pathology Department and Fungal Biology Group, University of Georgia, Athens, Georgia, United States of America.ORCID 0000-0002-7643-7634
Michelle MomanyPlant Biology Department and Fungal Biology Group, University of Georgia, Athens, Georgia, United States of America.ORCID 0000-0001-7110-063X
Marin T BrewerPlant Pathology Department and Fungal Biology Group, University of Georgia, Athens, Georgia, United States of America.ORCID 0000-0002-7064-6021
University of Georgia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aspergillus fumigatus is an opportunistic human pathogen that causes aspergillosis, a spectrum of environmentally acquired respiratory illnesses. It has a cosmopolitan distribution and exists in the environment as a saprotroph on decaying plant matter. Azoles, which target Cyp51A in the ergosterol synthesis pathway, are the primary class of drugs used to treat aspergillosis. Azoles are also used to combat plant pathogenic fungi. Recently, an increasing number of azole-naive patients have presented with pan-azole-resistant strains of A. fumigatus. The TR34/L98H and TR46/Y121F/T289A alleles in the cyp51A gene are the most common ones conferring pan-azole resistance. There is evidence that these mutations arose in agricultural settings; therefore, numerous studies have been conducted to identify azole resistance in environmental A. fumigatus and to determine where resistance is developing in the environment. Here, we summarize the global occurrence of azole-resistant A. fumigatus in the environment based on available literature. Additionally, we have created an interactive world map showing where resistant isolates have been detected and include information on the specific alleles identified, environmental settings, and azole fungicide use. Azole-resistant A. fumigatus has been found on every continent, except for Antarctica, with the highest number of reports from Europe. Developed environments, specifically hospitals and gardens, were the most common settings where azole-resistant A. fumigatus was detected, followed by soils sampled from agricultural settings. The TR34/L98H resistance allele was the most common in all regions except South America where the TR46/Y121F/T289A allele was the most common. A major consideration in interpreting this survey of the literature is sampling bias; regions and environments that have been extensively sampled are more likely to show greater azole resistance even though resistance could be more prevalent in areas that are under-sampled or not sampled at all. Increased surveillance to pinpoint reservoirs, as well as antifungal stewardship, is needed to preserve this class of antifungals for crop protection and human health.

Indexed as

AnimalsAntifungal AgentsAspergillosisAspergillus fumigatusAzolesDisease ReservoirsDrug Resistance, FungalHumansAntifungal AgentsAzoles

Identifiers

PMID34324607
PMCPMC8321103
OpenAlexW3186437563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.